QDENGA Dengue Vaccine: India’s First Approved Dengue Vaccine
India set to get its first approved dengue vaccine with QDENGA to be marketed in the private sector in the first six months of 2027. The vaccine, which has been developed by the Japanese drug manufacturing company, Takeda, has received marketing authorisation from the Indian Central Drugs Standard Control Organisation (CDSCO) in July 2026 for use among people aged between 4 and 60 years.
The development has increased the ways of dengue prevention, including controlling mosquitoes and minimizing exposure to Aedes mosquitoes.
QDENGA, also referred to as TAK-003, is a live attenuated tetravalent dengue vaccine.
It is intended to provide protection from the four types of the virus,
In 2024, WHO provided prequalification to QDENGA. It is given in two doses, three months apart.
According to the approved indication, it is not necessary to carry out tests on dengue infection before administering the vaccine.
In India, QDENGA has been licensed by CDSCO for use among the individuals aged 4-60 years.
But just because of such a license, this doesn’t mean all individuals aged between 4 and 60 would be able to get the vaccine. QDENGA will first become available in the private sector, and its price has not yet been disclosed.
Healthcare professionals can decide whether vaccination is necessary for the person.
India is developing its own dengue vaccine called DengiAll, and currently, these vaccines are regulated differently.
| Features | QDENGA | DengiAll |
| Developer | Takeda | Developed in India |
| Other name | TAK-003 | DengiAll |
| Vaccine type | Tetravalent | Tetravalent |
| Status in India | CDSCO-licensed | Undergoing large-scale clinical trials |
| Age range of the individuals that can be vaccinated | 4-60 years old | Not yet approved |
| Number of doses | 2 doses (3 months apart) | The schedule is under evaluation |
| Status according to WHO | Prequalified in 2024 | Pending |
DengiAll is undergoing large-scale clinical trials, and at the moment it cannot be considered an approved vaccine in India.
It is expected that QDENGA will be made available in India’s private market by the mid-2027, it also provided that all the local regulatory and commercial procedures have been completed successfully.
Takeda has reached an agreement with Dr Reddy’s Laboratories regarding the distribution of QDENGA in the private paediatric and adult market in India.
The cost and any future availability through public immunization programs have yet to be revealed.
Dengue is mainly spread through infected Aedes mosquitoes and may lead to symptoms like fever, body pain, and even severe dengue.
Vaccination would act as another prevention technique along with controlling of mosquitoes, removal of breeding sites, and protection from mosquito bites.
The significance of QDENGA in India’s case is that it brings in a licensed vaccine for dengue to India’s prevention picture. The extent of its significance would depend upon various aspects such as pricing, availability, and others.
India is getting one step closer to having a high-speed rail service after the Bharat-made…
The film titled ‘Mothers of Courage’ has been awarded the United Nations SDG Action Award…
The International Day for Biosphere Reserves is celebrated every year on 3rd November. This was…
Prema Rawat, a player from the Uttarakhand team made history by scoring the fastest half-century…
Indian swimmer Dhinidhi Desinghu created history by winning the bronze medal in the Women's 100m…
The tenure of the high-powered task force, led by Nandan Nilekani to reform the examination…